Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Melanoma 19Triple Negative Breast Neoplasms 14Stomach Neoplasms 13Breast Neoplasms 13Neoplasm Metastasis 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Neoplasms 9Carcinoma 9Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Esophageal Neoplasms 4Cholangiocarcinoma 4Thoracic Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lung Diseases 3

Interventions

Gemcitabine 13Cisplatin 10Capecitabine 7pembrolizumab 3Oxaliplatin 3Leucovorin 3Chemotherapy, Adjuvant 3durvalumab 2Watchful Waiting 2Fluorouracil 2Dihematoporphyrin Ether 2zanidatamab 1becatecarin 1Tegafur 1Taxes 1Somatostatin 1S 1 (combination) 1Platinum 1Phototherapy 1Photochemotherapy 1Ondansetron 1Neoadjuvant Therapy 1Laser Therapy 1Irinotecan 1Folfox protocol 1Fentanyl 1Escitalopram 1Epirubicin 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Gallbladder Neoplasms × pembrolizumab × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2026-04-15

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
158 enrolled 19 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡